{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T06:05:03Z","timestamp":1778997903648,"version":"3.51.4"},"reference-count":17,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T00:00:00Z","timestamp":1677369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Chirality"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ganirelix, a drug used in in vitro fertilization (IVF), prevents ovulation in women who are not ready to have children by inhibiting a gene that produces gonadotropin. Peptides are macromolecules that are able to preserve a predetermined shape while carrying out the structural and regulatory roles for which they were originally intended. Peptide structures can be altered in the production and storage processes. Therapeutic peptides' biological activity can be drastically altered by even small modifications in their primary and secondary structures. The molecules' secondary structures can be monitored by subjecting them to different processing or storage conditions. In our investigation, we used circular dichroism (CD) spectroscopy with two different software programs for secondary structure evaluation to look at how environmental factors like temperature and humidity affected the secondary structure of Ganirelix in an injectable formulation. The CD results revealed that the alpha\u2010helical (regular and distorted), beta\u2010sheet, beta\u2010strands (regular and distorted), beta\u2010turn, and random coil structures of temperature and humidity stressed generic drug products are comparable to reference\u2010listed drug.<\/jats:p>","DOI":"10.1002\/chir.23552","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T04:09:11Z","timestamp":1677470951000},"page":"427-434","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of effects of temperature and humidity on the secondary structure of Ganirelix in an injectable formulation and comparison with Orgalutran\u00ae using circular dichroism spectroscopy"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-2382","authenticated-orcid":false,"given":"Kumarswamy","family":"Ummiti","sequence":"first","affiliation":[{"name":"Department of Engineering Chemistry, College of Engineering Koneru Lakshmaiah Education Foundation  Guntur India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. V. Shanmukha","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Engineering Chemistry, College of Engineering Koneru Lakshmaiah Education Foundation  Guntur India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Muni","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Chemistry D.K. Government Degree College for Women  Nellore India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen Kumar","family":"Subbappa","sequence":"additional","affiliation":[{"name":"Slayback Pharma LLC  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,26]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"1","volume-title":"Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls","author":"Larisa W","year":"2019"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.12.051"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmx017"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201008400\u2010z"},{"key":"e_1_2_7_6_1","unstructured":"U.S. Food and drug administration.Antagon (Ganirelix Acetate) 1999.http:\/\/accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/21057_Antagon.cfm. (accessed: November 2022)."},{"key":"e_1_2_7_7_1","unstructured":"European Commission.Orgalutran 2000.http:\/\/drugs.com\/uk\/orgalutran.html. (accessed: December 2022)."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/02656730802149570"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389203003381315"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22695"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22686"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja0356176"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnmrs.2008.06.002"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005\u20102795(76)90062\u20103"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1006\/abio.1996.0084"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bb.17.060188.001045"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097\u20100134(19990515)35:3%3C307::AID\u2010PROT4%3E3.0.CO;2\u20103"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959\u2010440X(98)80017\u20101"}],"container-title":["Chirality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/chir.23552","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/chir.23552","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/chir.23552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T10:37:12Z","timestamp":1692441432000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/chir.23552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,26]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/chir.23552"],"URL":"https:\/\/doi.org\/10.1002\/chir.23552","archive":["Portico"],"relation":{},"ISSN":["0899-0042","1520-636X"],"issn-type":[{"value":"0899-0042","type":"print"},{"value":"1520-636X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,26]]},"assertion":[{"value":"2023-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}